Circulating adiponectin levels in patients with Atrial fibrillation

Circulation Journal

Volumn 72, Issue 7, 2008, Pages 1120-1124

  Shimano, Masayuki ^a   Shibata, Rei ^a   Tsuji, Yukiomi ^b   Kamiya, Hiromi ^a   Uchikawa, Tornohiro ^a   Harata, Shuji ^a   Mulo, Masahiro ^a   Ouchi, Noriyuki ^c   Indcn, Yasuya ^a   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adiponectin; Atrial fibrillation; Biomarkers; Fibrosis; Remodeling

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; PROCOLLAGEN N PROTEINASE;

ADULT; ARTICLE; BLOOD LEVEL; CONTROL GROUP; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

ADIPONECTIN; ADULT; AGED; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; COLLAGEN TYPE I; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; PREVALENCE; PROCOLLAGEN; VENTRICULAR REMODELING;

EID: 46849090339     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.1120     Document Type: Article

References (44)

1. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-1968.
2. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002; 415: 219-226.
3. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation 1999; 100: 87-95.
4. Anné W, Willems R, Holemans P, Beckers F, Roskams T, Lenaerts I, et al. Self-terminating AF depends on electrical remodeling while persistent AF depends on additional structural changes in a rapid atrially paced sheep model. J Mol Cell Cardiol 2007; 43: 148-158.
5. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-289.
6. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003; 14:561-566.
7. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007; 380: 24-30.
8. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004; 10: 1384-1389.
9. Liao Y, Takashima S, Maeda N, Ouchi N, Kasnamura K, Shimomura I, et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardio-vasc Res 2005; 67:705-713.
10. Shibata R, Sato K, Pimentel DR, Takaemura Y, Kihara S, Ohashi K, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005; 11: 1096-1103.
11. Shibata R, Sato K, Kumada M, Izumiya Y, Sonoda M, Kihara S, et al. Adiponectin accumulates in myocardial tissue that has been damaged by ischemia-reperfusion injury via leakage from the vascular compartment. Cardiovasc Res 2007; 74: 471-479.
12. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 2007; 115: 1408-1416.
13. Shibata R, Izumiya Y, Sato K, Papanicolaou K, Kihara S, Colucci WS, et al. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J Mol Cell Cardiol 2007; 42: 1065-1074.
14. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagama J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
15. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
16. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
17. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-89.
18. Otsuka F, Sugiyama S, Kojima S, Maruyoshi H, Funahashi T, Sakamoto T, et al. Hypoadiponectinemia is associated with impaired glucose tolerance and coronary artery disease in non-diabetic men. Circ J 2007; 71: 1703-1709.
19. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimto K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004; 43: 1318-1323.
20. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112: 1756-1762.
21. George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006; 92: 1420-1424.
22. McEntegart MB, Awede B, Petrie MC, Sattar N, Dunn FG, MacFarlane NG, et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: Relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 2007; 28: 829-835.
23. Tsutamoto T, Tanaka T, Sakai H, Ishikawa C, Fujii M, Yamamoto T, et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 2007; 28: 1723-1730.
24. Nakamura T, Funayama H, Kubo N, Yasu T, Kawakumi M, Saito M, et al. Association of hyperadiponectinemia with severity of ventricular dysfunction in congestive heart failure. Circ J 2006; 70: 1557-1562.
25. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141.
26. Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005; 20: 129-134.
27. Wang T J, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004; 292: 2471-2477.
28. Zacharias A, Schwann TA, Riordan C J, Durham S J, Shah AS, Habib RH. Obesity and risk of new-onset atrial fibrillation after cardiac surgery. Circulation 2005; 112: 3247-3255.
29. Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study. Am J Med 2005; 118: 489-495.
30. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98: 476-484.
31. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Am J Cardiol 1998; 82: 2N-9N.
32. Ostgren CJ, Merlo J, Rastam L, Lindblad U. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab 2004; 6: 367-374.
33. Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 2001; 104: 2118-21150.
34. McNamara RL, Brass LM, Drozda JP Jr, Go AS, Halperin JL, Kerr CR, et al. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: A report of the American College of Cardiology /American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Data Standards on Atrial Fibrillation). J Am Coll Cardiol 2004; 44: 475-495.
35. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: Evidence for independent roles of age and sex. Diabetologia 2003; 46: 459-469.
36. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360: 57-58.
37. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226-228.
38. Snehalatha C, Mukesh B, Simon M, Viswanathan V, Haffner SM, Ramachandran A. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care 2003; 26: 3226-3229.
39. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999; 79: 215-262.
40. Weber KT. Cardiac interstitium in health and disease: The fibrillar coUagen network. J Am Coll Cardiol 1989; 13: 1637-1652.
41. Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A, et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 2004; 109: 363-368.
42. Yoshihara F, Nishikimi T, Sasako Y, Hino J, Kobayashi J, Minatoya K, et al. Plasma atrial natriuretic peptide concentration inversely correlates with left atrial collagen volume fraction in patients with atrial fibrillation: Plasma ANP as a possible biochemical marker to predict the outcome of the maze procedure. J Am Coll Cardiol 2002; 39: 288-294.
43. Ohashi K, Iwatani H, Kihara S, Nakagawa Y, Komura N, Fujita K, et al. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol 2007; 27: 1910-1917.
44. Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshia Y, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003; 125: 1796-1807.